CILOSTAZOL INCREASES PATENCY AND DECREASES ADVERSE OUTCOMES IN PATIENTS SUBMITTED TO PERCUTANEOUS FEMOROPOPLITEAL STENT REVASCULARIZATION: A RANDOMIZED CONTROLLED TRIALS META-ANALYSIS

Alexandre Benjo,Daniel Garcia,J S Jenkins,Rhanderson Cardoso,Taina P Molina,Emad F Aziz,Tyrone J Collins

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2014）

引用 1|浏览1

暂无评分

摘要

Cilostazol is an oral antiplatelet agent currently indicated for the treatment of intermittent claudication. There is some evidence that it may reduce femoropopliteal stent restenosis after percutaneous intervention. We searched PubMed, Scopus, and Cochrane databases from 1966 through September

查看译文

关键词

percutaneous femoropopliteal stent revascularization,decreases adverse outcomes,meta-analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要